By Counterforce Health Team in Qalsody (tofersen) —

How to Get Qalsody (tofersen) Covered by Aetna CVS Health in Pennsylvania: A Step-by-Step Approval Guide

Quick Answer: Getting Qalsody (tofersen) Covered by Aetna CVS Health in Pennsylvania

Eligibility: You need a confirmed SOD1 gene mutation, ALS diagnosis, and prescription from a neurologist. Fastest path: Submit prior authorization with genetic testing results, baseline ALSFRS-R score, and neurofilament light chain levels. First step today: Contact your neurologist to order SOD1 genetic testing if not already done, then gather all required clinical documentation. Pennsylvania residents have strong appeal rights with a 50% success rate through the state's external review program launched in 2024.

Table of Contents

  1. Patient Profile: Who Qualifies for Qalsody
  2. Pre-Authorization Preparation
  3. Submission Process
  4. Initial Outcome and Common Responses
  5. Appeal Strategy (When Needed)
  6. Resolution and Approval Terms
  7. What We'd Do Differently
  8. Pennsylvania-Specific Appeal Rights
  9. Cost and Financial Support
  10. FAQ

Patient Profile: Who Qualifies for Qalsody

Qalsody (tofersen) is specifically for adults with ALS caused by mutations in the SOD1 gene. Here's what Aetna CVS Health requires for coverage consideration:

Core Requirements

  • Confirmed SOD1 mutation from genetic testing
  • ALS diagnosis with upper and lower motor neuron signs
  • Prescription by neurologist or neuromuscular specialist
  • Baseline measurements: ALSFRS-R score and elevated neurofilament light chain (NfL) levels
  • No invasive ventilation (oxygen via nasal cannula or BiPAP is acceptable)
Note: Only about 3% of sporadic ALS patients and 20-30% of familial ALS cases have SOD1 mutations, making genetic testing the critical first step.

The medication costs approximately $14,230-$14,754 per 100mg vial, with first-year treatment reaching $200,000-$220,000 at list price before rebates.

Pre-Authorization Preparation

Essential Documentation Checklist

✓ Genetic Testing Results

  • Laboratory confirmation of SOD1 mutation
  • Include specific variant identified
  • Ensure testing was performed by certified lab

✓ Clinical Documentation

  • Complete neurological evaluation
  • Evidence of upper and lower motor neuron involvement
  • Disease progression timeline
  • Current ALSFRS-R score (within past 6 months)

✓ Baseline Laboratory Values

  • Elevated plasma neurofilament light chain (NfL) levels
  • Recent vital capacity measurements
  • Other relevant lab work supporting ALS diagnosis

✓ Prior Treatment History

  • Documentation of riluzole or edaravone use (if applicable)
  • Response or lack thereof to conventional therapies
  • Any contraindications to standard treatments

Medical Necessity Letter Framework

Your neurologist should include:

  1. Patient's specific SOD1 mutation and its clinical significance
  2. ALS progression rate and functional decline
  3. Why Qalsody is appropriate for this patient's variant
  4. Treatment goals and expected monitoring plan
  5. References to FDA approval and clinical trial data

Submission Process

Step-by-Step Submission

1. Confirm Specialty Pharmacy Network Qalsody must be dispensed through CVS Specialty Pharmacy for Aetna members. Your prescriber will need to send the prescription directly to CVS Specialty.

2. Prior Authorization Submission

  • Submit through Aetna's provider portal or by fax
  • Include all documentation from preparation checklist
  • Request initial 6-month approval duration
  • Allow 30-45 days for standard review

3. Required Forms and Codes

  • Use appropriate ICD-10 codes for ALS (G12.21)
  • Include HCPCS code J3490 (unclassified biologics)
  • Specify intrathecal administration route

Dosing Requirements to Document

  • Loading phase: 100mg intrathecally every 14 days for 3 doses
  • Maintenance: 100mg intrathecally every 28 days thereafter
  • Administration site: Qualified medical facility with intrathecal capabilities

Initial Outcome and Common Responses

Likely Scenarios

Scenario 1: Approval (Less Common Initially) If approved, you'll receive authorization for 6 months with specific quantity limits and administration requirements.

Scenario 2: Denial (More Common) Common denial reasons include:

  • "Experimental/investigational" designation
  • Missing SOD1 genetic confirmation
  • Non-neurologist prescriber
  • Incomplete clinical documentation
  • "Not medically necessary" determination
Important: Recent CMS guidance (December 2024) directed Medicare Advantage plans to cover Qalsody for on-label SOD1-ALS use, strengthening appeal arguments for all insurers.

Understanding Your Denial Letter

Look for specific denial codes and reasons:

  • Prior authorization required: Resubmit with complete documentation
  • Non-formulary: Request formulary exception
  • Step therapy: Document failures/contraindications to required alternatives
  • Medical necessity: Prepare detailed clinical justification

Appeal Strategy (When Needed)

Level 1: Internal Appeal

Timeline: Submit within 180 days of denial Process:

  1. Submit additional clinical evidence
  2. Include updated medical necessity letter
  3. Reference CMS guidance on SOD1-ALS coverage
  4. Request expedited review if clinically urgent

Level 2: Peer-to-Peer Review

If initial appeal fails, request peer-to-peer review:

  • Prepare your neurologist for discussion with Aetna medical director
  • Focus on SOD1 mutation significance and lack of alternatives
  • Emphasize FDA approval and clinical trial data
  • Document the conversation outcome

Key Appeal Arguments

1. FDA Approval Status Qalsody received FDA approval specifically for SOD1-ALS based on biomarker data showing neurofilament light chain reduction.

2. Lack of Alternatives No other FDA-approved treatments specifically target SOD1-mediated ALS.

3. Clinical Urgency ALS progression is irreversible; delays in treatment may result in permanent functional loss.

4. Plan Policy Compliance Demonstrate how your case meets all stated prior authorization criteria.

Resolution and Approval Terms

Typical Approval Conditions

When approved, expect:

  • Duration: 6-month initial authorization
  • Quantity limits: Aligned with FDA dosing schedule
  • Site restrictions: Qualified intrathecal administration facility
  • Monitoring requirements: Regular ALSFRS-R assessments

Reauthorization Process

For continued coverage:

  • Submit reauthorization 30-60 days before expiration
  • Include updated ALSFRS-R scores
  • Document clinical benefit or stability
  • Provide ongoing monitoring results

What We'd Do Differently

Best Practices from Successful Cases

1. Front-Load Documentation Submit comprehensive clinical package initially rather than responding to requests for additional information.

2. Engage CVS Specialty Early Their clinical team can provide prior authorization support and identify potential issues before submission.

3. Leverage Multiple Specialists Consider involving ALS clinic coordinators and genetic counselors in documentation process.

4. Prepare for Appeals Assume initial denial and have appeal documentation ready immediately.

Common Mistakes to Avoid

  • Submitting without confirmed SOD1 mutation results
  • Using non-neurologist prescriber without consultation documentation
  • Missing baseline functional assessments
  • Inadequate medical necessity justification

Pennsylvania-Specific Appeal Rights

Independent External Review Program

Pennsylvania launched a state-supervised external review program in January 2024 with impressive results:

Success Rate: Approximately 50% of appeals are overturned Timeline:

  • Standard review: 45 days
  • Expedited review: 72 hours for urgent cases

How to Access:

  1. Complete Aetna's internal appeal process first
  2. Obtain Final Adverse Benefit Determination letter
  3. Submit external review request within 4 months
  4. Use Pennsylvania Insurance Department online portal

Resources:

Additional Pennsylvania Protections

Pennsylvania's Act 77 of 2024 provides additional specialty drug protections, including review processes for specialty drug designations by pharmacy benefit managers.

Cost and Financial Support

CVS Specialty Financial Assistance

CVS Specialty's CareTeam proactively connects patients with:

  • Manufacturer copay assistance programs
  • Patient assistance programs
  • External financial aid sources
  • Insurance benefits optimization

Biogen Support Services

Qalsody manufacturer support includes:

  • Prior authorization assistance
  • Appeal letter templates
  • Benefits investigation
  • Patient support coordinators

Contact: Available through Biogen Support Services

Pennsylvania State Programs

While no Qalsody-specific state programs exist, Pennsylvania residents may qualify for:

  • PACE/PACENET (for seniors)
  • Medical assistance programs
  • Disability-related pharmacy benefits

At Counterforce Health, we help patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals by creating targeted, evidence-backed responses. Our platform analyzes denial letters and plan policies to draft point-by-point rebuttals that align with each payer's specific requirements, pulling the right clinical evidence and procedural details that payers expect to see.

FAQ

Q: How long does Aetna CVS Health prior authorization take for Qalsody? A: Standard prior authorization decisions typically take 30-45 days. Expedited reviews for urgent cases may be completed within 72 hours.

Q: What if Qalsody is not on Aetna's formulary? A: Request a formulary exception with medical necessity documentation. Non-formulary status doesn't prevent coverage if medical necessity is established.

Q: Can I get an expedited appeal if my ALS is progressing rapidly? A: Yes. Document rapid functional decline and request expedited review, which Aetna must complete within 72 hours for urgent cases.

Q: Do I need to try other ALS medications first? A: Step therapy requirements vary, but Qalsody's unique mechanism for SOD1-ALS often exempts it from typical step therapy protocols.

Q: What happens if both internal and external appeals fail? A: You may file complaints with Pennsylvania Insurance Department and explore legal options, though this is uncommon for properly documented SOD1-ALS cases.

Q: How do I prove my SOD1 mutation is pathogenic? A: Use genetic testing from certified laboratories that specifically identify disease-causing variants. Include genetic counselor interpretation when available.

From Our Advocates

We've seen patients initially denied Qalsody coverage successfully obtain approval by strengthening their genetic testing documentation and emphasizing the lack of alternative SOD1-targeted therapies. The key is often working closely with specialty pharmacies like CVS to ensure all clinical criteria are clearly addressed in the initial submission, reducing the need for lengthy appeals processes.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and appeal processes may change. Always consult with your healthcare provider and insurance company for the most current requirements. For personalized assistance with complex appeals, consider working with organizations like Counterforce Health that specialize in turning insurance denials into successful approvals.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.